Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04521140 · ClinicalTrials.gov registry record · Phase 4

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery

A Phase 4 study of Intraocular Pressure and Corneal Edema, sponsored by Nicole Fram M.D..

Completed
Registry status
Phase 4
Development phase
36
Enrollment target
1
Study location

NCT04521140: Completed Phase 4 study of Intraocular Pressure and Corneal Edema, sponsored by Nicole Fram M.D..

NCT04521140 is a Phase 4 study of Intraocular Pressure and Corneal Edema that has completed, run by Nicole Fram M.D.. The registered enrollment target is 36 participants, below the 84-participant average among 9 other Intraocular Pressure trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04521140, a Phase 4 study of Intraocular Pressure and Corneal Edema, has completed, sponsored by Nicole Fram M.D..

COMPLETED
Registry status
Phase 4
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

Assessing the efficacy and safety of DEXTENZA, sustained release dexamethasone 0.4 mg insert following corneal transplant surgery (PKP, DSEK, DMEK) as compared to topical prednisolone acetate 1%.

Primary Outcome

as measured with the visual analog scale (VAS); between 0 and 100; 0 meaning no pain and 100 meaning worst pain possible

Interventions

  • DRUG Prednisolone Acetate 1% Oph Susp
  • DRUG Dextenza 0.4Mg Ophthalmic Insert

Study Locations (1)

California

  • Advanced Vision Care - Los Angeles

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2020-10-16
Est. Completion 2023-01-04
Phase Phase 4
Nicole Fram M.D.

4 total trials

What the finished NCT04521140 record still lists

NCT04521140 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 84-participant average among 9 other Intraocular Pressure trials with a reported enrollment target (57% lower).

The record links to 7 conditions, with Intraocular Pressure appearing as the primary indexed condition, and to 2 interventions - of which Prednisolone Acetate 1% Oph Susp is the first listed.

NCT04521140 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT04521140 about?

NCT04521140 is a clinical study titled "Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery". Assessing the efficacy and safety of DEXTENZA, sustained release dexamethasone 0.4 mg insert following corneal transplant surgery (PKP, DSEK, DMEK) as compared to topical prednisolone acetate 1%.

What is the current status of trial NCT04521140?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2020-10-16. Estimated completion is 2023-01-04.

What conditions does trial NCT04521140 study?

This clinical trial studies the following conditions: Intraocular Pressure, Corneal Edema, Ocular Pain, Corneal Defect, Corneal Transplant.

What interventions are being tested in trial NCT04521140?

The interventions under investigation include: Prednisolone Acetate 1% Oph Susp (DRUG), Dextenza 0.4Mg Ophthalmic Insert (DRUG).

Who is sponsoring clinical trial NCT04521140?

This trial is sponsored by Nicole Fram M.D., which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04521140 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Intraocular Pressure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04521140's enrollment target sits among peer trials

36 8th of 9 higher than 2 of 9 other Intraocular Pressure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Intraocular Pressure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00929006 · 36 participants · Early Phase 1

    Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

  • NCT01891318 · 36 participants · Phase 1

    Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

  • NCT02291848 · 36 participants · Phase 1

    Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

  • NCT02366819 · 36 participants · Phase 4

    Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04521140, the US trial registry maintained by the National Library of Medicine. NCT04521140 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.